Intellia Therapeutics insider filing shows fresh director equity award

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (NTLA) Form 4: Director Georgia Keresty reported new equity compensation dated 06/11/2025.

• 8,000 restricted stock units (RSUs) granted at $0 cost; each RSU converts into one common share.
• 11,450 stock options with a $8.37 exercise price; the option vests in full on the earlier of the first anniversary of grant or the next annual shareholder meeting and expires 06/10/2035.
• After the grant, Keresty directly owns 31,883 common shares.

No shares were sold or disposed of, and the filing reflects routine non-employee director compensation with negligible dilution and no impact on control or earnings.

Positive

• Equity alignment: Grant of 8,000 RSUs and 11,450 options increases director’s stake, reinforcing alignment with shareholders.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine director grant; no sales; neutral impact on NTLA shares.

The Form 4 records purely compensatory awards—8,000 RSUs and 11,450 options—issued to director Georgia Keresty. Because there is no disposition of shares, cash proceeds, or change in ownership of 10%+, the disclosure is administrative rather than market-moving. The exercise price of $8.37 is fixed for 10 years, but optionality value is contingent on long-term performance. Overall dilution is de-minimis relative to Intellia’s >75 million basic shares outstanding (not provided here but publicly available). I see no valuation impact or signalling beyond continued alignment of director and shareholder interests.

Corporate Governance Specialist

TL;DR: Standard equity award keeps board incentives aligned; governance-neutral.

The compensation structure—full vesting after one year or next AGM—mirrors common biotech peer practice and supports board retention. The absence of a Rule 10b5-1 trading plan checkbox indicates this was not part of a pre-arranged sale program. With Keresty’s total direct holding now 31,883 shares, her economic stake remains modest yet sufficient for fiduciary alignment. No red flags or unusual acceleration provisions were detected.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keresty Georgia

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/11/2025		A		8,000	A	$0.00	31,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.37	06/11/2025		A		11,450		(2)	06/10/2035	Common Stock	11,450	$0.00	11,450	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

Remarks:

Exhibit 24.1 - Power of Attorney.

	James Basta, attorney-in-fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did NTLA director Georgia Keresty receive on 06/11/2025?

She received 8,000 RSUs and 11,450 stock options with a $8.37 exercise price.

Were any Intellia Therapeutics shares sold in this Form 4 filing?

No. The filing only reports acquisitions; there were no dispositions of shares.

How many NTLA shares does Georgia Keresty own after the reported transactions?

Her direct beneficial ownership increased to 31,883 common shares.

When do the newly granted NTLA stock options expire and vest?

They expire on 06/10/2035 and vest in full on the earlier of one year from grant or the next annual shareholder meeting.

Was a Rule 10b5-1 trading plan involved in this transaction?

The Rule 10b5-1 checkbox was not marked, indicating no such plan governed this award.